Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul 28;14(15):3681.
doi: 10.3390/cancers14153681.

Traditional Systemic Treatment Options in Advanced Low-Grade Serous Ovarian Cancer after Successful Cytoreduction: A Systematic Review and Meta-Analysis

Rosa Montero-Macías  1 , Pascal Rigolet  2 , Elie Mikhael  1 , Jonathan Krell  3 , Vincent Villefranque  1 , Fabrice Lecuru  4   5 , Christina Fotopoulou  6
Affiliations
Review

Traditional Systemic Treatment Options in Advanced Low-Grade Serous Ovarian Cancer after Successful Cytoreduction: A Systematic Review and Meta-Analysis

Rosa Montero-Macías et al. Cancers (Basel). .

Abstract

Objective: We performed a systematic literature review and a subsequent meta-analysis to compare traditional treatment options, i.e., antihormonal and cytotoxic, in LGSOC.

Methods: We conducted a systematic literature review in MEDBASE and MEDLINE between September 2000 and June 2021 for women who received cytotoxic chemotherapy and/or antihormonal treatment after primary cytoreduction due to stage II-IV LGSOC and also at relapse. PFS and OS were calculated depending on the type of their adjuvant treatment. For each endpoint in the meta-analysis, pooled HR was calculated using the random effect model with the inverse variance weighted method. Only primary patients were included in the subsequent meta-analysis due to the small number of studies in the relapsed setting.

Results: Five eligible first-line studies were included. Systemic chemotherapy failed to provide a significant OS benefit when compared to no systemic treatment (pooled HR = 1.01, 95% CI [0.79, 1.29]) after successful cytoreduction. Moreover, systemic chemotherapy followed by antihormonal treatment also did not result to a significant PFS or OS benefit when compared to systemic chemotherapy alone (for PSF: pooled HR = 0.59, 95% CI [0.33, 1.04]; for OS: pooled HR = 0.83, 95% CI [0.50, 1.39]). There were insufficient data from studies in the recurrent setting to allow their inclusion in the meta-analysis.

Conclusions: In this meta-analysis, we failed to identify a traditional cytotoxic or antihormonal systemic treatment option that was associated with a significant OS or PFS benefit when administered following successful cytoreduction for advanced LGSOC. Prospective randomized studies are urgently warranted to define optimal adjuvant options in this challenging disease.

Keywords: adjuvant treatment; chemotherapy; hormonal therapy; low-grade serous ovarian cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
PRISMA Flow Diagram.
Figure 2
Figure 2
Meta-analysis for: (a) OS in patients with systemic chemotherapy alone, (b) for OS and (c) PFS for patients treated with additional antihormonal maintenance treatment after completion of systemic chemotherapy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Malpica A., Deavers M.T., Lu K., Bodurka D., Atkinson E.N., Gershenson D.M., Silva E.G. Grading Ovarian Serous Carcinoma Using a Two-Tier System. Am. J. Surg. Pathol. 2004;28:496–504. doi: 10.1097/00000478-200404000-00009. - DOI - PubMed
    1. Gadducci A., Cosio S. Therapeutic Approach to Low-Grade Serous Ovarian Carcinoma: State of Art and Perspectives of Clinical Research. Cancers. 2020;12:1336. doi: 10.3390/cancers12051336. - DOI - PMC - PubMed
    1. Bogani G., Maggiore U.L.R., Paolini B., Diito A., Martinelli F., Lorusso D., Raspagliesi F. The detrimental effect of adopting interval debulking surgery in advanced stage low-grade serous ovarian cancer. J. Gynecol. Oncol. 2019;30:e4. doi: 10.3802/jgo.2019.30.e4. - DOI - PMC - PubMed
    1. Cobb L.P., Sun C.C., Iyer R., Nick A.M., Fleming N.D., Westin S.N., Sood A.K., Wong K.K., Silva E.G., Gershenson D.M. The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance. Gynecol. Oncol. 2020;158:653–658. doi: 10.1016/j.ygyno.2020.06.498. - DOI - PubMed
    1. Crane E.K., Sun C.C., Ramirez P.T., Schmeler K.M., Malpica A., Gershenson D.M. The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer. Gynecol. Oncol. 2014;136:25–29. doi: 10.1016/j.ygyno.2014.11.005. - DOI - PMC - PubMed

LinkOut - more resources